On May 17, 2022 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Investment Conference. An on-demand webcast presentation will be available on Tuesday, May 24, 2022, at 7:00 a.m. ET (Press release, Regulus, MAY 17, 2022, https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-global-investment-conference-301549248.html [SID1234614771]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The on-demand webcast will be available under "Events and Presentations" through the investor relations section of the Company’s website at www.regulusrx.com and will be archived for 90 days following the presentation date.